Dr. Daniel Lebovic, MD

Dr. Lebovic practices at Henry Ford St. John Hospital in Detroit, Michigan, part of Henry Ford Health.

Dr. Lebovic's NPI, 1740302850, was assigned on April 6, 2007. Dr. Lebovic holds Michigan license 4301088178.

Dr. Lebovic's primary practice is Henry Ford St. John Hospital, at 22101 Moross Rd, Detroit, MI 48236 in Wayne County. The practice phone is (313) 343-4000.

Dr. Lebovic's primary practice is Henry Ford St. John Hospital in Detroit, Michigan, part of Henry Ford Health. Dr. Lebovic is also affiliated with Henry Ford Hospital. The medical group on file is Henry Ford St. John Hospital. Dmand AI also links Dr. Lebovic to 2 more hospitals, 2 group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lebovic practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Lebovic's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Lebovic is licensed in Michigan.

CMS data shows 1,363 Medicare services from Dr. Lebovic across 8 procedure codes in 2024, for 409 Medicare patients. Medicare paid $79,496 for them.

CMS counts 409 Medicare patients who saw Dr. Lebovic in 2024. The largest group is 65 to 74, with 172 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 18% are also on Medicaid. Their average risk score is 2.21, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lebovic's median patient age at 71, with 63% women.

In 2024, Dr. Lebovic wrote 1,831 Medicare Part D claims for 228 patients. 61% of them were for generic drugs. CMS names the drug for 1,538 of them, across 33 drugs with 11 or more claims each, at $7,497,584 in total drug cost. In 2023, CMS named 1,478 claims across 34 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Lebovic for performance year 2024, reported through an alternative payment model (APM). Dr. Lebovic accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lebovic as offering telehealth.

Dmand AI links 2 papers to Dr. Lebovic in 2011. The most frequent topics are Antineoplastic Combined Chemotherapy Protocols. Dr. Lebovic's most frequent co-authors are Melissa Alsina, MD, Rachid C. Baz, MD and Alberto A. Chiappori, MD.

CMS Open Payments shows 586 general payments to Dr. Lebovic from 40 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 89% of the total. Celgene Corporation paid the most, $150,366.